

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 December 2023 (28.12.2023)



(10) International Publication Number
WO 2023/249974 A3

(51) International Patent Classification:

C07D 487/20 (2006.01) A61K 31/519 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2023/025791

(22) International Filing Date:

20 June 2023 (20.06.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/353,729	20 June 2022 (20.06.2022)	US
63/444,523	09 February 2023 (09.02.2023)	US
63/460,201	18 April 2023 (18.04.2023)	US
63/470,621	02 June 2023 (02.06.2023)	US

(71) Applicant: **INCYCLIX BIO, INC.** [US/US]; 600 Park Office Drive, Suite 355, Research Triangle Park, NC 27709 (US).


(72) Inventors: **STRUM, Jay Copeland**; c/o Incyclix Bio, Inc., 600 Park Offices Drive, Suite 355, Research Triangle Park,

NC 27709 (US). **BISI, John E.**; c/o Incyclix Bio, Inc., 600 Park Offices Drive, Suite 355, Research Triangle Park, NC 27709 (US). **TRUB, Alec Gibson**; c/o Incyclix Bio, Inc., 600 Park Offices Drive, Suite 355, Research Triangle Park, NC 27709 (US).

(74) Agent: **BELLOWS, Brent R.** et al.; Knowles Intellectual Property Strategies, LLC, 400 Perimeter Center Terrace, Suite 200, Atlanta, GA 30346 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: CYCLIN-DEPENDENT KINASE 2 INHIBITORS FOR MEDICAL TREATMENT



(57) Abstract: Use of a pyrimidine-based selective cyclin-dependent kinase 2 (CDK2) of structure: (Compound I), or a pharmaceutically acceptable salt thereof or morphic form described herein for the treatment of disorders characterized by aberrant cellular division having amplified cyclin E activation and/or expression or aberrant cellular division disorders, CDK4/6 resistance, and/or endocrine therapy resistance, including but not limited to the treatment of tumors and cancers.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

01 February 2024 (01.02.2024)